Amy Eubanks, MD
Internal Medicine · Bremen, GANPI 1962441493
Payments from drug & device makers
Across 264 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$642
- Novo Nordisk$467
- Amgen$299
- AbbVie$293
- GSK$258
- AstraZeneca$257
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,28597%
- Education$1243%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 39 | $642 |
| Novo Nordisk | 31 | $467 |
| Amgen | 17 | $299 |
| AbbVie | 26 | $293 |
| GSK | 18 | $258 |
| AstraZeneca | 18 | $257 |
| Astellas Pharma US Inc | 8 | $224 |
| Lilly USA, LLC | 8 | $219 |
| Amarin Pharma, Inc. | 13 | $213 |
| Upsher-smith Laboratories LLC | 10 | $212 |
| Supernus Pharmaceuticals, Inc. | 12 | $191 |
| Boehringer Ingelheim | 10 | $187 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $155 |
| Phathom Pharmaceuticals, Inc. | 5 | $127 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $99 |
| Axsome Therapeutics, Inc. | 3 | $81 |
| Johnson & Johnson | 4 | $76 |
| Sumitomo Pharma America, Inc. | 3 | $55 |
| Novartis | 3 | $51 |
| Bayer | 2 | $47 |
| Mannkind Corporation | 3 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Merck | 3 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Valinor Pharma, LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$4,409 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 303 | $349,213 |
| MounjaroTirzepatide | 201 | $228,263 |
| EliquisApixaban | 232 | $186,349 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 172 | $164,067 |
| JardianceEmpagliflozin | 112 | $113,189 |
| Repatha SureclickEvolocumab | 118 | $111,714 |
| MyrbetriqMirabegron | 144 | $108,158 |
| CreonLipase/Protease/Amylase | 24 | $68,628 |
| XifaxanRifaximin | 24 | $68,626 |
| PercocetOxycodone Hcl/Acetaminophen | 13 | $55,778 |
| LinzessLinaclotide | 71 | $54,425 |
| JanuviaSitagliptin Phosphate | 39 | $39,076 |
| XareltoRivaroxaban | 39 | $34,950 |
| Praluent PenAlirocumab | 27 | $32,170 |
| GemtesaVibegron | 54 | $29,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $467 | $349,213303 claims |
| Lilly USA, LLCMounjaro, Trulicity | $219 | $241,656215 claims |
| PfizerEliquis, Nurtec Odt | $642 | $196,976243 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $258 | $193,498234 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $187 | $147,705158 claims |
| AbbVieCreon, Linzess, Restasis | $293 | $130,763107 claims |
| Astellas Pharma US IncMyrbetriq | $224 | $108,158144 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $155 | $68,62624 claims |
| AstraZenecaBrilinta, Farxiga, Symbicort | $257 | $43,04877 claims |
| MerckJanuvia | $39 | $39,07639 claims |
| Johnson & JohnsonXarelto | $76 | $34,95039 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $55 | $29,80554 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Bremen
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.